These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 10631622)

  • 41. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
    Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
    Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Repaglinide for type 2 diabetes mellitus.
    Med Lett Drugs Ther; 1998 May; 40(1027):55-6. PubMed ID: 9618664
    [No Abstract]   [Full Text] [Related]  

  • 43. Clinical experience with repaglinide in patients with non-insulin-dependent diabetes mellitus.
    Shapiro MS; Abrams Z; Lieberman N
    Isr Med Assoc J; 2005 Feb; 7(2):75-7. PubMed ID: 15729954
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus.
    Burge MR; Schmitz-Fiorentino K; Fischette C; Qualls CR; Schade DS
    JAMA; 1998 Jan; 279(2):137-43. PubMed ID: 9440664
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.
    Raskin P
    Diabetes Obes Metab; 2008 Dec; 10(12):1167-77. PubMed ID: 18494804
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of repaglinide and metformin monotherapy as an initial therapy in Chinese patients with newly diagnosed type 2 diabetes mellitus.
    Fang FS; Gong YP; Li CL; Li J; Tian H; Huang W; Wang LC; Li L
    Eur J Endocrinol; 2014 Jun; 170(6):901-8. PubMed ID: 24694876
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.
    Niemi M; Neuvonen PJ; Kivistö KT
    Clin Pharmacol Ther; 2001 Jul; 70(1):58-65. PubMed ID: 11452245
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [symbol: see text] Nateglinide and [symbol: see text] repaglinide for type 2 diabetes?
    Drug Ther Bull; 2003 Jul; 41(7):52-4. PubMed ID: 12879789
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
    Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
    Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preclinical and clinical studies on safety and tolerability of repaglinide.
    Schatz H
    Exp Clin Endocrinol Diabetes; 1999; 107 Suppl 4():S144-8. PubMed ID: 10522841
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Repaglinide administration improves brachial reactivity in type 2 diabetic patients.
    Manzella D; Grella R; Abbatecola AM; Paolisso G
    Diabetes Care; 2005 Feb; 28(2):366-71. PubMed ID: 15677794
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preprandial repaglinide decreases exogenous insulin requirements and HbA1c levels in type 2 diabetic patients taking intensive insulin treatment.
    Ozbek M; Erdogan M; Karadeniz M; Cetinkalp S; Ozgen AG; Saygili F; Yilmaz C; Tuzun M
    Acta Diabetol; 2006 Dec; 43(4):148-51. PubMed ID: 17211567
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Acarbose versus Repaglinide in Diabetes Treatment: A New Appraisal of Two Old Rivals.
    Pishdad R; Pishdad P; Pishdad GR
    Am J Med Sci; 2020 Apr; 359(4):212-217. PubMed ID: 32200914
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hypoglycemia during the Concomitant Use of Repaglinide and Clopidogrel in an Elderly Patient with Type 2 Diabetes and Severe Renal Insufficiency.
    Takayama K; Fujii K; Yamaguchi H; Miyoshi Y; Uehara Y; Nagata S; Obata Y; Kosugi M; Hazama Y; Yasuda T
    Intern Med; 2021; 60(6):905-910. PubMed ID: 33716254
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk of Hypoglycemia and Concomitant Use of Repaglinide and Clopidogrel: A Population-Based Nested Case-Control Study.
    Wei Y; Lin FJ; Lin SY; Wang CC
    Clin Pharmacol Ther; 2019 Dec; 106(6):1346-1352. PubMed ID: 31216051
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Single-dose pharmacokinetics of repaglinide in subjects with chronic liver disease.
    Hatorp V; Walther KH; Christensen MS; Haug-Pihale G
    J Clin Pharmacol; 2000 Feb; 40(2):142-52. PubMed ID: 10664920
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of repaglinide vs nateglinide for treatment of Japanese patients with type 2 diabetes mellitus.
    Kawamori R; Kaku K; Hanafusa T; Kashiwabara D; Kageyama S; Hotta N
    J Diabetes Investig; 2012 Jun; 3(3):302-8. PubMed ID: 24843581
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Severe thrombocytopenia due to repaglinide in a patient with type 2 diabetes.
    Katsuyama H; Hiraishi C; Hakoshima Y; Yanai H
    Diabetes Care; 2013 Mar; 36(3):e36. PubMed ID: 23431098
    [No Abstract]   [Full Text] [Related]  

  • 59. Risk of hypoglycemia associated with repaglinide combined with clopidogrel, a retrospective cohort study.
    Akagi Y; Iketaki A; Kimura H; Matsudaira Y; Yoshida T; Nishimura T; Kawano Y; Mano Y; Shigematsu E; Ujihara M
    J Pharm Health Care Sci; 2020; 6():5. PubMed ID: 32206324
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serious hypoglycemia associated with misuse of repaglinide.
    Flood TM
    Endocr Pract; 1999; 5(3):137-8. PubMed ID: 15251685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.